Velvet Worm Slime Reveals Its Sticky Secrets
The velvet worm, a squishy little predator that looks like the stretch-limo version of a caterpillar, has a whimsical MO: it administers death by Silly String.
In the leaf litter of tropical and temperate forests around the world, velvet worms stalk the night on dozens of stubby legs. The pocket-size predator—whose species range from less than half an inch to eight inches long—can barely see, so it bumbles around, hoping to literally bump into an edible bug such as a cricket or a woodlouse. When it finds one, the velvet worm uses nozzles on either side of its face to shoot jets of sticky slime at its victim.
'It happens so fast it's almost like they're sneezing,' says Matthew Harrington, a biochemist at McGill University who has studied velvet worms for a decade.
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
At first, the goo is a watery liquid, but in midair it transforms into jellylike ropes that ensnare the unlucky creature and stick it to the ground. As the prey struggles, the slime forms fibrous threads, and within seconds the substance hardens into a glasslike solid.
Scientists have been intrigued by velvet worm slime's adhesive properties for more than a century. (In the 1870s researchers puzzling over what makes it stick tried tasting it. The verdict: bitter.) Recent findings suggest the phase-shifting goo could inspire a new generation of recyclable bioplastics, according to research published by Harrington and his colleagues in the Proceedings of the National Academy of Sciences USA.
Previously, the researchers discovered that soaking the hardened fibers in water returned them to their liquid state—and by rubbing the resultant mess between their fingertips, they could get fibers as strong as nylon to re-form. That means 'everything we need to know about making these fibers is encoded in the proteins themselves,' Harrington says.
But isolating those proteins is easier said than done, the scientists found. The slime is so sensitive to touch that even standard laboratory techniques such as pipetting can trigger its phase shift. To avoid that sticky situation altogether, the scientists sequenced the RNA of proteins from the slime of velvet worms collected in Barbados, Singapore and Australia. Then they fed the RNA sequences into AlphaFold3, a program that uses artificial intelligence to predict protein shapes. For all three species, it 'spit out this horseshoe shape' rich in the amino acid leucine, Harrington says.
Although this structure is novel to materials scientists, it's old hat to evolution. A similar protein called a toll-like receptor is part of an ancient immune system feature found across plants, invertebrates and vertebrates. These receptors sit on the surface of immune cells, binding tightly to pieces of invading microbes and releasing them later. Harrington and his team suggest the horseshoe-shaped protein may use a similar 'host-guest' dynamic to grab onto other proteins in the slime, binding strongly but reversibly to form the powerful fibers. Those are magic words to materials scientists working on developing replacements for plastic that can be broken down easily and re-formed into new shapes.
These horseshoe proteins are a significant find, says Yendry Corrales Ureña, a researcher at Costa Rica's National Laboratory of Nanotechnology who studies velvet worm slime but wasn't involved in the study. She adds, however, that these proteins don't account for important properties of the slime such as its toughness or elasticity. 'They are just one piece of the larger puzzle.'
Julian Monge Najera, an ecologist at the University of Costa Rica who researches invertebrate evolution, says the fact that three velvet worm species from different continents have the same protein shape in their slime underscores how incredibly ancient velvet worms are and how long ago their chemical R&D must have occurred.
The fossil record shows that velvet worms have existed almost exactly as they do now for at least 300 million years, predating both dinosaurs and today's continents. 'If I could go back in a time machine, the velvet worms I would catch in the post-Cambrian period would be identical to the ones in Costa Rica's cloud forests today,' Monge Najera says—phase-shifting slime and all.
Harrington and his team are working to purify the horseshoe protein from the slime and confirm its structure via electron microscopy. 'We won't be milking velvet worms for slime to replace plastics,' Harrington says. 'But we hope to copy their chemical tricks.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
a day ago
- Medscape
Canagliflozin CV Benefits Appear to Be Dose-Dependent
Cardiovascular benefits associated with the SGLT2 inhibitor drug canagliflozin appear to be dose-dependent, with benefits in some key clinical endpoints — including mortality — observed only in the higher of the two key doses of 300 mg and 100 mg of the drug, new research shows. 'The benefit of canagliflozin on hard clinical endpoints may be dose-dependent, with the 300 mg dose showing a higher efficacy and a similar safety profile,' said first author Elias Elenjickal, MD, of the Research Institute of the McGill University Heath Centre, in Montreal, Quebec, in presenting the findings at the 62nd European Renal Association Congress 2025. Cardiovascular and renal benefits of SGLT2 inhibitor drugs are well established, and while dose-dependent effects have been reported in some pharmacokinetic studies, none — with the exception of the EMPA-REG OUTCOME trial (which was of empagliflozin) — have formally evaluated the impact of different doses on hard clinical endpoints, Elenjickal noted. To investigate whether dose indeed plays a role in those cardiovascular and renal endpoints with canagliflozin, Elenjickal and colleagues conducted a post-hoc analysis of the double-blind Canagliflozin Cardiovascular Assessment Study (CANVAS) study, which was part of the pivotal CANVAS Program. The CANVAS Program included the CANVAS and CANVAS-Renal studies. The results of the two trials were published together as part of the CANVAS program, not independently. The CANVAS study included 4330 patients with type 2 diabetes and a high cardiovascular risk, including known cardiovascular disease (CVD) or more than 2 risk factors for CVD. Those patients were randomized 1:1:1 to treatment with canagliflozin 100 mg, canagliflozin 300 mg, or placebo. Patients in the study had a median age of 61 years, 66% were male, and baseline characteristics between the groups were similar. With a mean follow-up of 74 months, those in the canagliflozin 300 mg group showed significantly greater reductions in the composite cardiovascular endpoint, including non-fatal myocardial infarction, stroke, or cardiovascular death, compared with placebo (hazard ratio [HR], 0.82; P = .04) after adjustment for factors including age, sex, and history of CVD. However, these differences were not observed between canagliflozin 100 mg and placebo for the composite endpoint (HR, 0.95; P = .55). There were no significant differences between the two canagliflozin doses and the incidence of the composite renal endpoint that included doubling of serum creatinine, end-stage kidney disease, or renal death, compared with placebo (HR, 0.48 for canagliflozin 100 mg; P = .03; HR, 0.41 for canagliflozin 300 mg; P = .01). Those in the 300 mg dose group were less likely to have progression of albuminuria to a higher stage (A1 to A2, or A2 to A3), compared with placebo (HR, 0.83; P = .006), but the difference was not significant with the 100 mg dose (HR, 0.94; P = .33). Importantly, all-cause mortality was significantly lower with the 300 mg dose compared with placebo (HR, 0.78; P =.03), while the 100 mg group only showed a trend toward lower mortality (HR, 0.89; P = .29). There were no significant differences between the two dose groups and placebo in terms of the incidence of acute kidney injury, while the 300 mg group had a trend towards fewer severe hyperkalemia episodes (adjusted HR, 0.61; P = .27). There were no differences observed in safety outcomes between the two dose groups or placebo. A Gender Difference? Of note, a further subgroup analysis showed an effect of gender on hospitalization rates for heart failure events: with males in the 300 mg group having a significantly decreased risk of heart failure hospitalization vs placebo (HR,.62), while females in the 300 mg group had an increased risk (HR, 1.72; P for interaction .03). In the 100 mg group, males also had a lower risk for heart failure hospitalization vs females (HR, 0.65 vs HR, 1.05; P for interaction .37). As a caveat, Elenjickal noted that males did have a higher burden of CVD at baseline (65% vs 46%). 'Overall, we found that canagliflozin 300 mg significantly reduced major adverse cardiac events, and reduction in all-cause mortality was observed only with a 300 mg dose: not with a 100 mg dose,' Elenjickal said. 'There is evidence of a dose-dependent effect with canagliflozin, which is unique among other SGLT2 inhibitors for hard clinical endpoints,' Elenjickal said. The CANVAS study was funded by Janssen Research and Development; number NCT01032629 . Elenjickal reported an educational grant from Pfizer.
Medscape
2 days ago
- Medscape
Music Strikes a Chord for Brain Health
Music's influence on the brain is documented in conditions ranging from dementia, to epilepsy. Both music participation and appreciation are tied to improvements in executive function and memory so how close are we to harnessing music as a targeted therapeutic tool. One researcher at the forefront of this work is Edward Large, PhD, a professor at the University of Connecticut in Storrs, Connecticut, and director of its Music Dynamics Laboratory. He told Medscape Medical News that he is optimistic about research suggesting that music can help, 'not just with depression and anxiety but with more profound neurological and psychological disorders.' However, he added that music's benefits aren't yet fully understood. Robert Zatorre, PhD, founding co-director of the International Laboratory for Brain, Music, and Sound Research in Montreal, Quebec, Canada, cautions against overstating its therapeutic power. 'Music is not a magic pill; it's not a panacea; it doesn't cure everything,' said Zatorre who is also a professor at the Montreal Neurological Institute at McGill University, Montreal, Quebec, Canada. Instead, it's important to define under what circumstances music could be beneficial and in what ways. 'And that's where the research is right now' he said. Robert Zatorre, PhD One challenge is music's deeply personal nature — what resonates with one person may leave another unmoved. Variables such as culture, age, personal history, social context, and even the nature of the neurological condition can influence how someone will respond to music-based interventions, said Zatorre. Brain Rhythms and Memory Large, a former president of the Society for Music Perception and Cognition and a musician himself, believes that one of the most important messages from research is the effect that music has on the rhythm of the brain. Brain rhythms or waves, also known as neural oscillations, are patterns of brain activity associated with various cognitive processes and behaviors. In healthy brains, slow theta waves (4-8 Hz) and fast gamma waves (30-100 Hz) work together (coupling) to encode and retrieve new memories. Alzheimer's disease (AD) is characterized by disruptions in gamma waves and atypical cross-frequency coupling. Edward Large, PhD 'Music is really the most powerful stimulus we have for synchronizing brain rhythms,' said Large. His group is testing whether stimulating synchrony in the gamma frequency can help treat AD. 'That's the frequency at which neurons in the hippocampus synchronize when they're retrieving a memory', he said. Noninvasive, gamma-frequency, auditory-visual stimulation has been shown to improve AD-related biomarkers and memory in animal models. Large is CEO of Oscillo Biosciences which is developing music based interventions for humans. He explained how such interventions might work: The individual listens to self-selected music and watches a rhythmic light stimulus that is synchronized to the music as their brain waves are monitored via electroencephalography. The light show works in concert with the music to stimulate theta and gamma neural rhythms and phase-amplitude coupling (See photo). It takes both the music and the synchronized light to have a similar effect to that seen for transcranial alternating-current stimulation, he said. An early test of Oscillo Biosciences' music-based intervention for AD Parkinson's Disease (PD) In addition to its potential memory boosting, music can help improve motor control. A music app was shown to improve gait and mood in patients with PD. Daniel J. Levitin, PhD, a neuroscientist and professor emeritus of psychology at McGill University noted in a recent interview with CBC Radio, that music's steady beat can act as 'an external timekeeper' for patients with PD, helping them to walk better because of the auditory stimulation. For multiple sclerosis (MS), Levitin said that music can activate non-demyelinated circuits in order to help with motor control. He echoed Zatorre's view that while the idea of a music prescription is appealing, what works best for a patient seems to be highly individualized. 'It's not like there is a single healing song or a list of healing songs,' he said in the interview. Instead, brain scans show that different types of songs can produce 'almost identical' brain activity in the limbic system, which is closely involved in experiencing pleasure, Levitin added. The Pleasure Principle The pleasure that music brings may be the source of its positive effects. 'I'm convinced that a lot of the benefits of these musical interventions act via the reward system,' said Zatorre who has conducted several related studies and authored a chapter on ' Musical Enjoyment and the Reward Circuits of the Brain ' for a book on Music and Mind edited by opera singer Renée Fleming. By engaging the reward system 'it has knock-on effects on a lot of behaviors and cognitions, including social cognition and memory and language,' he said. Zatorre theorized that music heard by a patient with a memory disorder will activate the reward pathway and simultaneously enhance the retrieval of certain memories. 'That's something that has been observed anecdotally in many patients with neurodegenerative disorders,' he said. There is evidence that the connectivity of the auditory and reward systems is preserved in people with mild cognitive impairment and early AD opening up a potential pathway for early treatment. 'I'm not sure we're there yet. But it's something that people are excited about,' said Zatorre. Familiar music tends to elicit a greater neural response, especially in older people, because once we reach a certain age, we know what we like and sticking to that brings enjoyment, which is linked to dopamine, explained Zatorre. The reward system is highly reactive in younger people. 'We not only fall in love with people [more easily] at that age, we fall in love with all sorts of things and places and movies and music. And that tends to stay with us,' Zatorre said. Large is currently conducting a functional MRI study in patients with AD that compares music that is self-selected and 'meaningful' to the participants with music that is merely familiar. The meaningful music activates important parts of the brain such as the auditory cortex, hippocampus, and reward centers more than the familiar music, he reported. 'So if you're trying to have an impact on your brain, I think you should listen to the music that you love.' Sing Like There's Nobody Listening? A number of recent studies have suggested that physically participating in music may be even better for the brain than passively listening (Figure). In a large nested study published last year, playing a musical instrument was linked to better executive function in older adults, with stronger links for woodwind instruments. Keyboard playing was associated with better working memory compared to not playing any instrument. This study did not show any significant associations between listening to music and cognitive performance but singing was associated with better executive function. Group singing may be particularly beneficial. A Finnish study tied singing in a choir to enhanced brain-structure connectivity across the lifespan of participants with no neurologic diagnoses at baseline. Another recent study in 50 patients with chronic aphasia after stroke found that those assigned to participate in weekly sessions of group singing had improved communication and responsive speech production 5 months later compared to those who received standard of care. 'It has to do with the vocal motor control, the ability to control your larynx and your breathing and your articulators, as well as the vocalization that singing requires as opposed to speaking,' said Zatorre, who was not involved with the research. He added that the social aspect of the intervention is also important, especially the 'singing together with other people who are suffering the same difficulties as you.' Hope for the Tone Deaf But what about people with congenital amusia ie, the tone deaf? Zatorre noted that about 50% of people who are tone deaf have perfect rhythm. 'They may not have the pitch correct, but they still are on time. So they can clap, or tap, or march, or dance, along to the beat,' he said. While many may think they are tone deaf, it's estimated that only 1.5%of the general population have true congenital amusia and even fewer also have no rhythm. 'They may not enjoy the music itself but could enjoy the more social aspects of it. It's enjoying bonding with others, even if you're singing off-key,' said Zatorre. He pointed out that patients with aphasia usually don't sing very well, 'but that's not the point.' Instead, the goal is improved outcome, he added. As the saying goes 'sing like there's nobody listening.' Music As Preventive Medicine? Could music be used as a preventive intervention to stave off, say, dementia in younger at-risk individuals? 'I think the answer is [that] we don't really know,' Large said. Although there are still questions about whether amyloid beta (Aβ) plaques are a cause or a symptom of AD, it's been shown that there is a desynchrony of rhythms in the gamma frequency band before a buildup of Aβ plaques occurs, he explained. 'I think that offers some hope that these rhythm-based therapies might have a preventive impact,' said Large. Zatorre acknowledged that research on music as a preventive intervention is 'quite scarce,' but noted that adding music can still improve quality of life. 'Music is an important art form that almost all people are sensitive to. If you're having a better quality of life, that will enhance everything. Even if it doesn't prevent the formation of plaques in your brain, you will still have a happier existence. And then if you do develop any type of degenerative disorder, you'll have more tools in your toolbox to help you cope,' he said. However, Zatorre noted that the same could be said for cooking or exercise or anything else that gives pleasure to an individual. 'I worry that music may have been a bit oversold to people, especially from those who are promoting a website or some type of self-help product. So I think caution is in order,' he said.
Scientific American
2 days ago
- Scientific American
Velvet Worm Slime Reveals Its Sticky Secrets
The velvet worm, a squishy little predator that looks like the stretch-limo version of a caterpillar, has a whimsical MO: it administers death by Silly String. In the leaf litter of tropical and temperate forests around the world, velvet worms stalk the night on dozens of stubby legs. The pocket-size predator—whose species range from less than half an inch to eight inches long—can barely see, so it bumbles around, hoping to literally bump into an edible bug such as a cricket or a woodlouse. When it finds one, the velvet worm uses nozzles on either side of its face to shoot jets of sticky slime at its victim. 'It happens so fast it's almost like they're sneezing,' says Matthew Harrington, a biochemist at McGill University who has studied velvet worms for a decade. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. At first, the goo is a watery liquid, but in midair it transforms into jellylike ropes that ensnare the unlucky creature and stick it to the ground. As the prey struggles, the slime forms fibrous threads, and within seconds the substance hardens into a glasslike solid. Scientists have been intrigued by velvet worm slime's adhesive properties for more than a century. (In the 1870s researchers puzzling over what makes it stick tried tasting it. The verdict: bitter.) Recent findings suggest the phase-shifting goo could inspire a new generation of recyclable bioplastics, according to research published by Harrington and his colleagues in the Proceedings of the National Academy of Sciences USA. Previously, the researchers discovered that soaking the hardened fibers in water returned them to their liquid state—and by rubbing the resultant mess between their fingertips, they could get fibers as strong as nylon to re-form. That means 'everything we need to know about making these fibers is encoded in the proteins themselves,' Harrington says. But isolating those proteins is easier said than done, the scientists found. The slime is so sensitive to touch that even standard laboratory techniques such as pipetting can trigger its phase shift. To avoid that sticky situation altogether, the scientists sequenced the RNA of proteins from the slime of velvet worms collected in Barbados, Singapore and Australia. Then they fed the RNA sequences into AlphaFold3, a program that uses artificial intelligence to predict protein shapes. For all three species, it 'spit out this horseshoe shape' rich in the amino acid leucine, Harrington says. Although this structure is novel to materials scientists, it's old hat to evolution. A similar protein called a toll-like receptor is part of an ancient immune system feature found across plants, invertebrates and vertebrates. These receptors sit on the surface of immune cells, binding tightly to pieces of invading microbes and releasing them later. Harrington and his team suggest the horseshoe-shaped protein may use a similar 'host-guest' dynamic to grab onto other proteins in the slime, binding strongly but reversibly to form the powerful fibers. Those are magic words to materials scientists working on developing replacements for plastic that can be broken down easily and re-formed into new shapes. These horseshoe proteins are a significant find, says Yendry Corrales Ureña, a researcher at Costa Rica's National Laboratory of Nanotechnology who studies velvet worm slime but wasn't involved in the study. She adds, however, that these proteins don't account for important properties of the slime such as its toughness or elasticity. 'They are just one piece of the larger puzzle.' Julian Monge Najera, an ecologist at the University of Costa Rica who researches invertebrate evolution, says the fact that three velvet worm species from different continents have the same protein shape in their slime underscores how incredibly ancient velvet worms are and how long ago their chemical R&D must have occurred. The fossil record shows that velvet worms have existed almost exactly as they do now for at least 300 million years, predating both dinosaurs and today's continents. 'If I could go back in a time machine, the velvet worms I would catch in the post-Cambrian period would be identical to the ones in Costa Rica's cloud forests today,' Monge Najera says—phase-shifting slime and all. Harrington and his team are working to purify the horseshoe protein from the slime and confirm its structure via electron microscopy. 'We won't be milking velvet worms for slime to replace plastics,' Harrington says. 'But we hope to copy their chemical tricks.'
